Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
CASI Pharmaceuticals Inc. (CASIF) had Stock-Based Compensation of $2.99M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$7.22M |
|
$-13.05M |
|
$3.53M |
|
$3.69M |
|
$17.89M |
|
$-10.66M |
|
$-2.37M |
|
$-13.04M |
|
$-13.04M |
|
$-13.04M |
|
$-13.05M |
|
$-13.05M |
|
$-13.04M |
|
$-10.66M |
|
$-10.66M |
|
18.54M |
|
18.54M |
|
$-0.37 |
|
$-0.37 |
|
| Balance Sheet Financials | |
$13.46M |
|
$6.97M |
|
$12.19M |
|
$25.65M |
|
$49.67M |
|
-- |
|
$13.26M |
|
$62.93M |
|
$-37.28M |
|
$-37.50M |
|
$-37.28M |
|
20.56M |
|
| Cash Flow Statement Financials | |
$-20.75M |
|
$0.95M |
|
$11.25M |
|
$13.47M |
|
$5.63M |
|
$-7.84M |
|
|
Stock-Based Compensation |
$2.99M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.27 |
|
-- |
|
-- |
|
-- |
|
-0.63 |
|
51.14% |
|
-147.67% |
|
-147.67% |
|
-- |
|
-180.52% |
|
-180.70% |
|
$-20.77M |
|
-- |
|
-- |
|
-- |
|
0.28 |
|
2.21 |
|
1.76 |
|
50.99 |
|
35.00% |
|
34.80% |
|
-50.88% |
|
35.00% |
|
$-1.81 |
|
$-1.12 |
|
$-1.12 |
|